What Caught Our Eye: A New GOP Health Plan, Looming Uncertainty for Insurers, Sharing Genetic Cancer Risks with Children, and More
What Caught Our Eye (WCOE), April 21, 2017 What Caught Our Eye is our week-in-review blog series, where we recap the cancer policy articles, studies, and stories that caught our attention. |
In the Spotlight
Trumpcare is back. And worse than ever.
House GOP members are floating a new health plan. Here’s what’s in it. https://t.co/9R3uWsbp8F
— Vox (@voxdotcom) April 20, 2017
Affordable Care Act
“Bare Market: What Happens if Places Have No Obamacare Insurers?”
What would happen if all the Obamacare insurers left a given market? We may soon find out. https://t.co/QnS7wNfJu3 pic.twitter.com/5eWZfaImDE
— The Upshot (@UpshotNYT) April 19, 2017
“Health Insurers Asked Trump Administration for Reassurance on Obamacare. They Didn’t Get It.”
Health insurers asked the Trump administration for reassurance on Obamacare. They didn’t get it. https://t.co/owtXt9Css3
— Post Economy (@PostEconomy) April 18, 2017
“Tom Price’s big test: Keep Obamacare afloat”
Tom Price's big test: Keep Obamacare afloat https://t.co/FgoPhW6ODT
— POLITICO Pulse (@POLITICOPulse) April 19, 2017
“White House Pressures GOP Leaders on Obamacare”
White House thinks vote will happen Wednesday. Hill Republicans are not in same hurry to rush a health care vote. https://t.co/y5rhh6bGNv
— Josh Dawsey (@jdawsey1) April 20, 2017
Cancer Policy
“FDA Approves Drug for Hodgkin Lymphoma”
The FDA has approved pembrolizumab (Keytruda®) for some adult and pediatric patients with classical Hodgkin lymphoma https://t.co/vNawsluRLr pic.twitter.com/uvGp6WRWG7
— National Cancer Institute (@theNCI) April 18, 2017
Coping with Cancer
“When to Tell Daughters About a Genetic Breast Cancer Risk”
When to Tell Daughters About a Genetic Breast Cancer Risk https://t.co/aPkU4KyQA3
— NYTimes Well (@nytimeswell) April 20, 2017
“Relationships and Metastatic Breast Cancer”
https://twitter.com/cancernews247/status/855124941204635648
More From “What Caught Our Eye” »
Follow us on Twitter: @CancerAdvocacy